- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Wildflower Marijuana Makes Research Agreement with Biologic Nutrigenomics
Wildflower Marijuana Inc. (CSE:SUN) announced that it’s entered into an agreement with Biologic Nutrigenomics Research Corp. under which Biologic will conduct medical research on Wildflower’s products and help with the development of new products.
Wildflower Marijuana Inc. (CSE:SUN) announced that it’s entered into an agreement with Biologic Nutrigenomics Research Corp. under which Biologic will conduct medical research on Wildflower’s products and help with the development of new products.
As quoted in the press release:
Wildflower has been developing cannabis products to address demands in the nutraceutical, pharmacological and recreational cannabis sectors. The company intends to bring products to market that are backed by solid scientific study demonstrating their efficacy. By using a science-based approach, the company will be able to further enhance the effectiveness of all its products.
Franco Cavaleri, president and chief science officer at Biologic, commented:
As much as the current movement to legalize and make cannabis more readily available is an exciting business prospect, it is more important to take a serious leadership role in the mining of this natural medicine’s full therapeutic potential to advance medical research and treatment of disease. Cannabis comprises a plethora of constituents that range in pharmacological activity from anti-inflammatory, analgesic (pain killing) and anti-cancer to neuro-protective and neuro-corrective. However, clinical and wet lab research reliability and repeatability have fallen short due to lack of standardization and sophistication of historical research models. With a corporate mission dedicated to extract the full pharmacological potential of this medicinal agent and some insight that gives us a head start with the right biological mechanisms and models, research using formal medical models to investigate novel cannabinoid-signalling pathways in the framework of complex disease pathologies to improve efficacy, reliability and acceptability in mainstream medicine [will allow the company] to better serve humanity and global health care with reliable, low-risk medicines exclusive to the Wildflower brand.
Click here to read the full Wildflower Marijuana Inc. (CSE:SUN) press release.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.